Financial
FY2025 revenue $4.66bn (+15.6%); operating margin 19.6%; net income $836.3m.
Cash $2.00bn; debt $1.24bn.
Dexcom
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Strong
Customer rating
No reviews yet
Financial health
Band: StrongListed: DXCM
FY2025 revenue $4.66bn (+15.6%); operating margin 19.6%; net income $836.3m.
Cash $2.00bn; debt $1.24bn.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$4.7bn | +15.6% | US$911.8m | US$836.3m | Dexcom |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Oct 2025: A proposed consumer class action filed in the US District Court for the Central District of California alleges Dexcom marketed its G7 monitor as superior while selling devices prone to alert failures; the claims are unproven and no company response was reported.
Cyber & information governance
Oct 2026: Dexcom disclosed a cyber incident after targeted voice-phishing in which unauthorised parties accessed limited information from internal documents; it says products and operations were unaffected and the incident was contained. NHS DSPT status not yet checked.
Regulatory & clinical safety
Sep 2025: FDA classed Dexcom's correction of its G7 and ONE+ apps (missed 'Sensor Failed' alerts) as the most serious recall type; no injuries were reported. In Mar 2025 an FDA warning letter said unapproved G6/G7 sensor changes amounted to misbranding.
Contract performance
No contract terminations, disputes or significant NHS contract news involving Dexcom found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.